These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 17634553

  • 1. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM, Saigal B, Tran H, Donato NJ.
    Clin Cancer Res; 2007 Jul 15; 13(14):4233-44. PubMed ID: 17634553
    [Abstract] [Full Text] [Related]

  • 2. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
    Sen B, Saigal B, Parikh N, Gallick G, Johnson FM.
    Cancer Res; 2009 Mar 01; 69(5):1958-65. PubMed ID: 19223541
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM, Saigal B, Talpaz M, Donato NJ.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.
    Clin Sci (Lond); 2012 Jan 01; 122(1):13-24. PubMed ID: 21751967
    [Abstract] [Full Text] [Related]

  • 5. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
    Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB.
    Cancer Res; 2006 Jun 01; 66(11):5542-8. PubMed ID: 16740687
    [Abstract] [Full Text] [Related]

  • 6. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.
    Cancer Chemother Pharmacol; 2008 Nov 01; 62(6):1065-74. PubMed ID: 18301894
    [Abstract] [Full Text] [Related]

  • 7. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
    Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.
    Cancer Res; 2007 Mar 15; 67(6):2800-8. PubMed ID: 17363602
    [Abstract] [Full Text] [Related]

  • 8. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M, Lou B, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J.
    Cancer Chemother Pharmacol; 2013 Jul 15; 72(1):35-44. PubMed ID: 23712327
    [Abstract] [Full Text] [Related]

  • 9. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.
    J Thorac Cardiovasc Surg; 2013 Feb 15; 145(2):531-8. PubMed ID: 23142123
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P, Zhang W, Gorlick R, Kolb EA.
    Clin Cancer Res; 2009 May 15; 15(10):3416-22. PubMed ID: 19447875
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
    Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q.
    Anticancer Drugs; 2011 Jan 15; 22(1):79-88. PubMed ID: 20881478
    [Abstract] [Full Text] [Related]

  • 12. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
    Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.
    Oncotarget; 2015 Dec 29; 6(42):44675-87. PubMed ID: 26625308
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC, Seoane S, Ocaña A, Pandiella A.
    Clin Cancer Res; 2011 Sep 01; 17(17):5546-52. PubMed ID: 21670084
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
    Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J, Seiden MV.
    Clin Cancer Res; 2006 Nov 15; 12(22):6844-52. PubMed ID: 17121906
    [Abstract] [Full Text] [Related]

  • 17. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV.
    Mol Pharmacol; 2007 Nov 15; 72(5):1137-45. PubMed ID: 17675586
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
    Wei J, Ma L, Li C, Pierson CR, Finlay JL, Lin J.
    Curr Cancer Drug Targets; 2019 Nov 15; 19(7):571-582. PubMed ID: 30332965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.